The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much more weight loss than any approved drug. By Gina Kolata Gina Kolata has ...

One of Eli Lilly’s most promising new obesity drugs helped patients lose about 28.7% of their body weight while also reducing pain associated with knee osteoarthritis. The drug giant’s LLY stock was ...

Eli Lilly LLY0.50%increase; green up pointing triangle said its next generation weight-loss drug retatrutide helped people lose up to 28.7% of their body weight after more than a year of treatment, ...

A next-generation obesity shot from Eli Lilly & Co. helped patients lose almost a quarter of their body weight, potentially making the experimental drug the most potent weight-loss medicine yet. The ...

A new weight-loss drug that Eli Lilly is testing is helping patients in a late-stage trial lose an average of 28.7% of their body weight and offered "substantial" relief from osteoarthritis pain. In ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Eli Lilly’s ...

Eli Lilly on Monday, Dec. 1 slashed prices of its blockbuster weight loss drug Zepbound for consumers who buy the prescription medication directly from the drugmaker. Lilly's price cuts ranged from ...

There might soon be a new weight loss treatment king on top. This week, Eli Lilly posted the first large-scale trial results of its experimental combination drug retatrutide—and it’s a whopper of a ...

Retatrutide shows highest weight loss to date in trial Lilly says trial departures due to perceived excessive weight loss Retatrutide shows elevated skin-related side effects Dec 11 (Reuters) - Eli ...

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...